Minovia Therapeutics

Company Overview

Snapshot

Founded in June 2025 by Natalie Yivgi-Ohana, Minovia Therapeutics operates with 1–10 employees. The company has raised $28.35M across 5 funding rounds from 3 investors. In June 2025, Minovia Therapeutics announced a proposed business combination with Launch One Acquisition Corp. to become a Nasdaq-listed mitochondrial therapy company.

Business overview

Minovia Therapeutics is a clinical-stage biotechnology company focused on developing Mitochondrial Augmentation Technology (MAT), an investigational platform utilizing mitochondrial transplantation. This platform includes cell-therapy approaches and proprietary analytical assays/biomarkers designed to measure mitochondrial health. The company's programs target rare mitochondrial diseases and age-related conditions, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In September 2024, Minovia Therapeutics received FDA clearance for its IND application for a Phase Ib clinical trial of MNV-201 in Low Risk Myelodysplastic Syndrome. This clearance signals significant progress in advancing its lead product candidate through regulatory pathways, validating the potential of its Mitochondrial Augmentation Technology for broader therapeutic applications beyond rare mitochondrial diseases and indicating a positive trajectory for clinical development.

Company Intelligence Q&A

What was the significant corporate development for Minovia Therapeutics in June 2025?

In June 2025, Minovia Therapeutics and Launch One Acquisition Corp. announced a proposed business combination. This transaction was intended to create a Nasdaq-listed mitochondrial therapy company.

What regulatory milestone did Minovia Therapeutics achieve in September 2024?

In September 2024, Minovia Therapeutics announced FDA clearance of its Investigational New Drug (IND) application for a Phase Ib clinical trial of MNV-201, targeting Low Risk Myelodysplastic Syndrome.

What was the outcome of the proposed business combination with Launch One Acquisition Corp. in February 2026?

In February 2026, Launch One Acquisition Corp. announced that it would not proceed with the merger with Minovia Therapeutics, indicating the proposed business combination was ultimately not completed.

What strategic collaboration did Minovia Therapeutics announce in July 2021?

In July 2021, Minovia Therapeutics announced a strategic collaboration with Astellas for novel mitochondrial cell therapy programs, aiming to advance its Mitochondrial Augmentation Technology.

When did Minovia Therapeutics receive FDA clearance for a Phase II clinical trial of MNV-201 in Pearson Syndrome?

In April 2025, Minovia Therapeutics announced FDA clearance of its second IND application, for a.